semaglutide alzheimer trial GLP-1 receptor agonist fails to halt Alzheimer's disease Semaglutide fails to slow Alzheimer's

Although patients with obesity can experience substantial benefits from a weekly injection of 2.4 milligrams (mg) of semaglutide the currently approved dose taken by patients in the U.S

But as clinicians increasingly prescribe them for broader metabolic benefits, researchers wanted to know if these drugs behave differently when it comes to kidney health, cardiovascular outcomes, and overall mortality

GLP-1, which stands for Glucagon-like peptide-1, is a hormone produced by special cells in the intestines

10.1080/19390211.2022.2075072 J Diet

Nasal Spray Seen as Easy and Effective Way to Deliver Glutathione, a Parkinsons Therapy Written by | A pilot study found that a nasal spray may be a promising and quickly effective way of delivering glutathione (GSH), and of increasing GSH levels in the brain of Parkinsons disease (PD) patients